France Neurological Biomarkers Market Size, Share, and COVID-19 Impact Analysis, By Application (Alzheimer’s, Parkinson’s, Multiple Sclerosis, and Autism), By Type (Genomic, Proteomic, Metabolomic, and Imaging), and France Neurological Biomarkers Market Insights, Industry Trend, Forecasts to 2035

France Neurological Biomarkers Market Insights Forecasts to 2035

• The France Neurological Biomarkers Market Size was estimated at USD 373.1 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 13.19% from 2025 to 2035
• The France Neurological Biomarkers Market Size is Expected to Reach USD 1457.2 Million by 2035

The France Neurological Biomarkers Market is anticipated to reach USD 1457.2 million by 2035, growing at a CAGR of 13.19% from 2025 to 2035. Rising neurological disorders, advanced diagnostic technologies, and growing demand for early disease detection drive growth.

Market Overview

The France neurological biomarkers market involves the study and application of specific biological markers used to diagnose and monitor neurological disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and stroke. Neurological biomarkers are measurable substances found in bodily fluids like blood and cerebrospinal fluid that provide valuable information about disease presence, progression, and treatment efficacy. This market encompasses various diagnostic technologies, including molecular assays and imaging techniques, which enable accurate and early detection of neurological conditions. Key stakeholders include healthcare providers, research organizations, and pharmaceutical companies focused on developing and utilizing biomarkers for improved clinical outcomes. The market also benefits from ongoing research and innovation within the country’s robust healthcare and biomedical sectors. With increasing investments in neurodiagnostic tools and collaborative efforts between public and private entities, the France neurological biomarkers market continues to evolve, supporting advancements in personalized medicine and targeted therapies for neurological diseases.

Report Coverage

This research report categorizes the market for the France neurological biomarkers market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France neurological biomarkers market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France neurological biomarkers market.

Driving Factors

The growth of the neurological biomarkers market in France is fueled by the escalating incidence of neurological diseases and the urgent demand for precise, early diagnostic tools. Innovations in molecular diagnostics and neuroimaging have revolutionized biomarker identification, enabling better disease tracking and tailored therapies. Significant funding from both government initiatives and private sector research accelerates progress in this field. Moreover, heightened awareness among clinicians and patients about the benefits of biomarker-based diagnosis further boosts adoption, supporting sustained market expansion in the coming years.

Restraining Factors

High costs of biomarker development and diagnostic tests limit market growth. Limited skilled professionals and stringent regulatory requirements create barriers. Variability in biomarker accuracy and the absence of standardized protocols further hinder widespread clinical adoption and slow market expansion.

Market Segmentation

The France neurological biomarkers market share is classified into application and type.

• The Alzheimer’s segment held the highest market share in 2024 and is expected to grow at a remarkable CAGR during the forecast period.

The France neurological biomarkers market is segmented by application into Alzheimer’s, Parkinson’s, multiple sclerosis, and autism. Among these, the Alzheimer’s segment held the highest market share in 2024 and is expected to grow at a remarkable CAGR during the forecast period. The growth in the segment is due to the widespread prevalence of Alzheimer’s and the critical need for early and accurate diagnosis. This growth is further supported by extensive research efforts focused on identifying reliable biomarkers for Alzheimer’s, enabling timely intervention and improved patient management.

• The proteomic segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The France neurological biomarkers market is segmented by type into genomic, proteomic, metabolomic, and imaging. Among these, the proteomic segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segment growth is driven by its critical role in identifying protein-based indicators associated with neurological disorders. Proteomic biomarkers offer valuable insights into disease mechanisms and progression, making them essential for accurate diagnosis and treatment monitoring.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France neurological biomarkers market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Sanofi
• Ipsen HQ
• Epigene Labs
• Owkin
• Bioserenity
• Others

Recent Developments:

• In May 2025, Sanofi announced its acquisition of Vigil Neuroscience for $470 million to enhance its neurological drug portfolio, particularly in Alzheimer's treatment. This acquisition includes Vigil's oral drug candidate, VG-3927, currently in development for Alzheimer's therapy.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at France, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the France neurological biomarkers market based on the below-mentioned segments:

France Neurological Biomarkers Market, By Application

• Alzheimer’s
• Parkinson’s
• Multiple Sclerosis
• Autism

France Neurological Biomarkers Market, By Type

• Genomic
• Proteomic
• Metabolomic
• Imaging